Government Waste: Paxlovid Spending Questions Vaccine Efficacy
Submitted by MAGA
Posted 3 hours ago
**Taxpayer Money Down the Drain: New Study Questions Billions Spent on Pfizer's Paxlovid**
In a shocking revelation that raises eyebrows about government spending, a new study has found that Pfizer's antiviral drug Paxlovid offers little to no significant benefit for vaccinated high-risk adults.
Conducted via two large-scale clinical trials involving over 4,200 participants, the findings indicate that Paxlovid did not reduce hospitalization or death among the vaccinated population, raising critical questions about the billion-dollar investment of taxpayer dollars in this unproven treatment.
The trials, conducted in the U.K. and Canada, demonstrated that hospitalization rates for those taking Paxlovid were nearly identical to those receiving standard care. In the U.K. trial, 0.8% of the treatment group was hospitalized compared to 0.7% in the control group, a difference deemed statistically non-significant.
Despite the disappointing results, the U.S. government has already spent a staggering $12 billion purchasing nearly 24 million treatment courses at about $530 each.
Critics have since pointed to a lack of accountability in the government's procurement decisions, emphasizing the apparent disconnect between early optimistic projections for Paxlovid and the reality presented by the new evidence.
Initially, Pfizer claimed their drug reduced hospitalization rates by nearly 90%, prompting federal leaders to pour billions into its procurement. Now that studies reveal no significant benefit for those who are vaccinated, it appears the government may have been misled.
The timing of the release has also raised questions, with nearly a two-year gap between the trial’s conclusion and publication. During this time, Pfizer reported astronomical revenue from Paxlovid, accumulating $18.9 billion in 2022 alone.
Demands for transparency have surfaced, as scrutiny intensifies. The findings indicate a need for a reevaluation of how COVID-19 treatments are modernized to better serve a population that now possesses varying degrees of immunity due to vaccination and previous infections.
This entire episode is reminiscent of other instances where governmental decisions have led to wasteful spending. As we move forward, it is crucial for American taxpayers to scrutinize not only drug efficacy but also the motivations behind government spending in the healthcare sector.
The misallocation of funds could send shockwaves through the economy, particularly as the nation faces other pressing issues.
As we reflect on these revelations, one can only hope that our leaders prioritize accountability and make wiser decisions with taxpayers' hard-earned dollars in the future.
Sources:
economiccollapse.report
theamericanconservative.com
naturalnews.com
In a shocking revelation that raises eyebrows about government spending, a new study has found that Pfizer's antiviral drug Paxlovid offers little to no significant benefit for vaccinated high-risk adults.
Conducted via two large-scale clinical trials involving over 4,200 participants, the findings indicate that Paxlovid did not reduce hospitalization or death among the vaccinated population, raising critical questions about the billion-dollar investment of taxpayer dollars in this unproven treatment.
The trials, conducted in the U.K. and Canada, demonstrated that hospitalization rates for those taking Paxlovid were nearly identical to those receiving standard care. In the U.K. trial, 0.8% of the treatment group was hospitalized compared to 0.7% in the control group, a difference deemed statistically non-significant.
Despite the disappointing results, the U.S. government has already spent a staggering $12 billion purchasing nearly 24 million treatment courses at about $530 each.
Critics have since pointed to a lack of accountability in the government's procurement decisions, emphasizing the apparent disconnect between early optimistic projections for Paxlovid and the reality presented by the new evidence.
Initially, Pfizer claimed their drug reduced hospitalization rates by nearly 90%, prompting federal leaders to pour billions into its procurement. Now that studies reveal no significant benefit for those who are vaccinated, it appears the government may have been misled.
The timing of the release has also raised questions, with nearly a two-year gap between the trial’s conclusion and publication. During this time, Pfizer reported astronomical revenue from Paxlovid, accumulating $18.9 billion in 2022 alone.
Demands for transparency have surfaced, as scrutiny intensifies. The findings indicate a need for a reevaluation of how COVID-19 treatments are modernized to better serve a population that now possesses varying degrees of immunity due to vaccination and previous infections.
This entire episode is reminiscent of other instances where governmental decisions have led to wasteful spending. As we move forward, it is crucial for American taxpayers to scrutinize not only drug efficacy but also the motivations behind government spending in the healthcare sector.
The misallocation of funds could send shockwaves through the economy, particularly as the nation faces other pressing issues.
As we reflect on these revelations, one can only hope that our leaders prioritize accountability and make wiser decisions with taxpayers' hard-earned dollars in the future.
Sources:
economiccollapse.report
theamericanconservative.com
naturalnews.com
Latest News